As obesity treatment continues to evolve, emerging therapies are expanding the possibilities for personalized care beyond traditional approaches.
This educational series explores the science behind novel pharmacologic pathways, equipping clinicians with the foundational knowledge needed to evaluate new treatment options based on mechanism of action, patient phenotype, and long-term therapeutic goals—not just weight-loss outcomes.
By building this understanding now, learners will be better prepared to integrate the next generation of obesity therapies into evidence-based clinical practice.
Explore the resources, engage with the content, and take the next step in delivering patient-centered, guideline-informed care.
Activities and Resources
A Multi-Pathway Rationale for the Next Therapeutic Current
Activity coming soon!
Faculty: Robert F. Kushner, MD, MS, FACP, FTOS, DABOM and Lee M. Kaplan, MD, PhD
To preview the content, click here to download the resource.
The Satiety Current: Amylin Biology as a Systems Signal
Activity coming soon!
Faculty: Robert F. Kushner, MD, MS, FACP, FTOS, DABOM and Matthew R. Hayes, PhD
Resource to preview content coming soon!
The Phenotype Breakers: Heterogeneity, Signals, and Who Might Benefit From Which Biology
Activity coming soon!
Faculty: Robert F. Kushner, MD, MS, FACP, FTOS, DABOM and Andres Acosta, MD, PhD, DABOM
Resource to preview content coming soon!
Reaching the Shoreline: Emerging Amylin-Based Therapies and Trial Signals
Activity coming soon!
Faculty: Robert F. Kushner, MD, MS, FACP, FTOS, DABOM and W. Timothy Garvey, MD, MACE
Resource to preview content coming soon!